CORRELATION OF DYSLIPIDEMIA/ HYPERLIPIDEMIA AND BLOOD PRESSURE IN CARDIOVASCULAR DISEASE PATIENTS
DOI:
https://doi.org/10.71000/xpp8v668Keywords:
Hypertension, Dyslipidemia, , Cardiovascular Disease, Obesity, Blood Pressure, , Risk Factors, AtherosclerosisAbstract
Background: Hypertension and dyslipidemia are among the leading contributors to cardiovascular disease (CVD) morbidity and mortality. These conditions frequently coexist, amplifying the risk of atherosclerosis and cardiac events. Dyslipidemia, characterized by elevated total cholesterol, low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and triglycerides, alongside low high-density lipoprotein (HDL), is further exacerbated by obesity. Despite the well-established individual risks, their interrelationship—especially in hypertensive CVD patients with obesity—requires deeper investigation to enable earlier intervention and more precise management.
Objective: To determine the relationship between lipid profile parameters and blood pressure in cardiovascular disease patients and evaluate how CVD status, obesity, gender, and age influence lipid abnormalities among hypertensive individuals.
Methods: This cross-sectional observational study was conducted over six months at CMA Research Lab Lahore, DHQ Hospital Sahiwal, Social Security Hospital Lahore, and Punjab Institute of Cardiology Lahore. A total of 103 patients aged 30–70 years were enrolled via non-probability convenience sampling. Inclusion criteria comprised patients with confirmed dyslipidemia and hypertension (≥140/90 mmHg), while those with secondary hypertension, stage 4+ chronic kidney disease, or recent myocardial infarction were excluded. Blood pressure was measured using a digital sphygmomanometer, and lipid profiles were analyzed using automated chemistry analyzers. Statistical analysis involved SPSS, with Pearson’s correlation, independent t-tests, and chi-square tests; p-values <0.05 were considered significant.
Results: Among 103 patients, 65 (63.1%) were males and 38 (36.9%) females, with most aged 40–49 years (29.1%). Hypertensive patients had significantly elevated total cholesterol (232.34 ± 34.18 mg/dL), LDL (143.94 ± 30.80 mg/dL), VLDL (53.16 ± 16.91 mg/dL), and triglycerides (273.16 ± 90.76 mg/dL) compared to non-hypertensives (p < 0.05). In hypertensive CVD patients, total cholesterol (223.79 ± 41.03 mg/dL) and VLDL (53.79 ± 16.03 mg/dL) were significantly higher than in non-CVD hypertensives. Obese hypertensive individuals had higher total cholesterol (227.91 ± 36.50 mg/dL), LDL (137.21 ± 34.88 mg/dL), VLDL (54.07 ± 16.27 mg/dL), and cholesterol/HDL ratio (5.74 ± 1.04) than non-obese counterparts (p < 0.05).
Conclusion: There is a clear association between hypertension and dyslipidemia, further intensified by obesity and cardiovascular disease status. These findings advocate for early lipid screening, lifestyle changes, and targeted therapeutic strategies to prevent cardiovascular complications in hypertensive patients.
References
Xie L, Kim J, Almandoz JP, Clark J, Mathew MS, Cartwright BR, et al. Anthropometry for predicting cardiometabolic disease risk factors in adolescents. Obesity (Silver Spring). 2024;32(8):1558-67.
Zhao L, Zheng L, Wang R, Gong X, Wu Y, Han S, et al. Association between triglyceride glucose combined with body mass index and hypertension in the NHANES 2017 to 2020. Sci Rep. 2025;15(1):9092.
Yang S, Shi X, Liu W, Wang Z, Li R, Xu X, et al. Association between triglyceride glucose-body mass index and heart failure in subjects with diabetes mellitus or prediabetes mellitus: a cross-sectional study. Front Endocrinol (Lausanne). 2023;14:1294909.
Liu X, Sun X, Zhang Y, Jiang W, Lai M, Wiggins KL, et al. Association Between Whole Blood-Derived Mitochondrial DNA Copy Number, Low-Density Lipoprotein Cholesterol, and Cardiovascular Disease Risk. J Am Heart Assoc. 2023;12(20):e029090.
Mehranfar S, Jalilpiran Y, Ejtahed HS, Seif E, Shahrestanaki E, Mahdavi-Gorabi A, et al. Association of dietary phytochemical index with cardiometabolic risk factors. Int J Vitam Nutr Res. 2023;93(6):559-76.
Seyed Khoei N, Wagner KH, Sedlmeier AM, Gunter MJ, Murphy N, Freisling H. Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank. Cardiovasc Diabetol. 2022;21(1):54.
Cifuentes L, Campos A, Sacoto D, Ghusn W, De la Rosa A, Feris F, et al. Cardiovascular Risk and Diseases in Patients With and Without Leptin-Melanocortin Pathway Variants. Mayo Clin Proc. 2023;98(4):533-40.
Aggarwal R, Yeh RW, Joynt Maddox KE, Wadhera RK. Cardiovascular Risk Factor Prevalence, Treatment, and Control in US Adults Aged 20 to 44 Years, 2009 to March 2020. Jama. 2023;329(11):899-909.
Shetty NS, Gaonkar M, Pampana A, Patel N, Morrison AC, Reiner AP, et al. Cardiovascular Risk Factors and Genetic Risk in Transthyretin V142I Carriers. JACC Heart Fail. 2025;13(1):91-101.
Chen Y, Du J, Zhou N, Song Y, Wang W, Hong X. Correlation between triglyceride glucose-body mass index and hypertension risk: evidence from a cross-sectional study with 60,283 adults in eastern China. BMC Cardiovasc Disord. 2024;24(1):270.
Hamedi-Shahraki S, Mir F, Amirkhizi F. Food Insecurity and Cardiovascular Risk Factors among Iranian Women. Ecol Food Nutr. 2021;60(2):163-81.
Kalhan AC, Kalhan TA, Romandini M, Bitencourt FV, Cooray UMP, Leite FRM, et al. Insulin resistance and periodontitis: Mediation by blood pressure. J Periodontal Res. 2025;60(3):226-35.
Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474-89.
Rojas-Martínez R, Escamilla-Nuñez C, Castro-Porras L, Gómez-Velasco D, Romero-Martínez M, Aguilar-Salinas CA. [Not Available]. Salud Publica Mex. 2024;66(3, may-jun):277-87.
Deng H, Hu P, Li H, Zhou H, Wu X, Yuan M, et al. Novel lipid indicators and the risk of type 2 diabetes mellitus among Chinese hypertensive patients: findings from the Guangzhou Heart Study. Cardiovasc Diabetol. 2022;21(1):212.
Zhu J, Zhang Y, Wu Y, Xiang Y, Tong X, Yu Y, et al. Obesity and Dyslipidemia in Chinese Adults: A Cross-Sectional Study in Shanghai, China. Nutrients. 2022;14(11).
Li C, Zhang Z, Luo X, Xiao Y, Tu T, Liu C, et al. The triglyceride-glucose index and its obesity-related derivatives as predictors of all-cause and cardiovascular mortality in hypertensive patients: insights from NHANES data with machine learning analysis. Cardiovasc Diabetol. 2025;24(1):47.
Totoń-Żurańska J, Mikolajczyk TP, Saju B, Guzik TJ. Vascular remodelling in cardiovascular diseases: hypertension, oxidation, and inflammation. Clinical Science. 2024 Jul;138(13):817-50.
Saheera S, Krishnamurthy P. Cardiovascular changes associated with hypertensive heart disease and aging. Cell transplantation. 2020 Apr 21; 29:0963689720920830.
Chruściel P, Stemplewska P, Stemplewski A, Wattad M, Bielecka-Dąbrowa A, Maciejewski M, Penson P, Bartlomiejczyk MA, Banach M. Associations between the lipid profile and the development of hypertension in young individuals–the preliminary study. Archives of Medical Science: AMS. 2022;18(1):25.
Adorni MP, Ronda N, Bernini F, Zimetti F. High density lipoprotein cholesterol efflux capacity and atherosclerosis in cardiovascular disease: pathophysiological aspects and pharmacological perspectives. Cells. 2021 Mar 5;10(3):574.
Vekic J, Zeljkovic A, Cicero AF, Janez A, Stoian AP, Sonmez A, Rizzo M. Atherosclerosis development and progression: the role of atherogenic small, dense LDL. Medicina. 2022 Feb 16;58(2):299.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 M. Saim Qasim, Shahid Sultan, Tasra Bibi, Muhammad Mushtaq, Usama Abid, Sheraz Ali, M. Tayyab, Gulam Mustafsa, Ahram Hussain, Muhammad Faizan (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
